Abstract
Type 2 diabetes is a progressive disease characterized by the need for additional antidiabetic agents overtime to maintain a stable level of glycemic control. The discovery of the glucagon like peptide 1, 1 of the 2 major incretins, was pivotal to the development of novel therapies, which can be used in individuals with type 2 diabetes. Two classes of drugs, GLP-1 receptor agonists and dipeptidyl peptidase inhibitors, provide comparable or superior glycemic effects to previous antidiabetic agents without increasing side effects, such as weight gain and hypoglycemia. Therefore, they represent valuable additions to the current therapeutic options for type 2 diabetes.
Original language | English (US) |
---|---|
Pages (from-to) | 307-318 |
Number of pages | 12 |
Journal | Current Diabetes Reports |
Volume | 13 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2013 |
Externally published | Yes |
Keywords
- Cardiovascular risk factors
- DPP-4
- DPP-4 inhibitors
- GLP-1
- GLP-1 receptor agonists
- Hypoglycemia
- Incretin
- Type 2 diabetes
- Weight loss
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism